Clinical risk factors for neuroleptic malignant syndrome

被引:21
作者
Berardi, D
Dell'Atti, M
Amore, M
De Ronchi, D
Ferrari, G
机构
[1] Univ Bologna, Inst Psychiat, I-40123 Bologna, Italy
[2] Univ Parma, Inst Psychiat, I-43100 Parma, Italy
关键词
neuroleptic malignant syndrome; risk factors; psychomotor agitation; catatonia; disorganization;
D O I
10.1002/hup.376
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Pharmacological risk factors for neuroleptic malignant syndrome (NMS) are better defined than clinical risk factors. We examined the psychopathological status preceding the onset of NMS in 20 patients. We evaluated four key psychiatric symptoms (psychomotor agitation, catatonia, disorganization and confusion) and grouped them into definite clinical syndromes. Six patients presented with an acute and severe catatonic syndrome, with all the four key psychiatric symptoms. Twelve patients presented with an acute and severe disorganized psychotic episode, with two or three key psychiatric symptoms, but not catatonia. Our study suggests that a clinical syndrome of acute disorganization, in addition to acute catatonia, is a potential clinical risk factor for NMS. The two syndromes, which can occur in the context of different mental disorders, are related to each other as both implicate alteration in behavioural monitoring, and were, in our experience, unresponsive to neuroleptics. In conclusion, we hypothesize that the recognition of these two syndromes should reduce NMS occurrence. We recommend a judicious use of neuroleptics not only in patients with acute catatonia, but also in patients with acute disorganization. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:99 / 102
页数:4
相关论文
共 26 条
  • [1] American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5
  • [2] Atypical neuroleptic malignant syndrome associated with clozapine treatment
    Amore, M
    Zazzeri, N
    Berardi, D
    [J]. NEUROPSYCHOBIOLOGY, 1997, 35 (04) : 197 - 199
  • [3] Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: A case-control study
    Berardi, D
    Amore, M
    Keck, PE
    Troia, M
    Dell'Atti, M
    [J]. BIOLOGICAL PSYCHIATRY, 1998, 44 (08) : 748 - 754
  • [4] Catatonia and the neuroleptics: Psychobiologic significance of remote and recent findings
    Blumer, D
    [J]. COMPREHENSIVE PSYCHIATRY, 1997, 38 (04) : 193 - 201
  • [5] The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder
    Bouffard, R
    Hechtman, L
    Minde, K
    Iaboni-Kassab, F
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2003, 48 (08): : 546 - 554
  • [6] Catatonia .2. Treatment with lorazepam and electroconvulsive therapy
    Bush, G
    Fink, M
    Petrides, G
    Dowling, F
    Francis, A
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1996, 93 (02) : 137 - 143
  • [7] NEUROLEPTIC MALIGNANT SYNDROME
    CAROFF, SN
    MANN, SC
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 1993, 77 (01) : 185 - 202
  • [8] DOSE EQUIVALENCE OF ANTI-PSYCHOTIC DRUGS
    DAVIS, JM
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1974, 11 : 65 - 69
  • [9] NEUROLEPTIC CATATONIA AND ITS RELATIONSHIP TO PSYCHOGENIC CATATONIA
    FRICCHIONE, GL
    [J]. BIOLOGICAL PSYCHIATRY, 1985, 20 (03) : 304 - 313
  • [10] GELENBERG AJ, 1976, LANCET, V1, P1339